WallStSmart

Encompass Health Corp (EHC)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Encompass Health Corp generates 133892% more annual revenue ($6.21B vs $4.63M). NIVF leads profitability with a 24.2% profit margin vs 10.0%. EHC earns a higher WallStSmart Score of 71/100 (B).

EHC

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 7.5Value: 6.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.12

NIVF

Avoid

34

out of 100

Grade: F

Growth: 2.7Profit: 5.5Value: 5.0Quality: 7.5
Piotroski: 4/9Altman Z: 4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EHCSignificantly Overvalued (-51.6%)

Margin of Safety

-51.6%

Fair Value

$74.82

Current Price

$122.09

$47.27 premium

UndervaluedFair: $74.82Overvalued

Intrinsic value data unavailable for NIVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EHC2 strengths · Avg: 9.5/10
PEG RatioValuation
0.4110/10

Growing faster than its price suggests

Return on EquityProfitability
23.9%9/10

Every $100 of equity generates 24 in profit

NIVF5 strengths · Avg: 9.8/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
79.4%10/10

Every $100 of equity generates 79 in profit

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.0710/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.2%9/10

Keeps 24 of every $100 in revenue as profit

Areas to Watch

EHC1 concerns · Avg: 3.0/10
Debt/EquityHealth
1.093/10

Elevated debt levels

NIVF4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.25M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-4.7%2/10

Revenue declined 4.7%

Operating MarginProfitability
-184.3%1/10

Operating margin of -184.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : EHC

The strongest argument for EHC centers on PEG Ratio, Return on Equity. PEG of 0.41 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on Price/Book, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.2% and operating margin at -184.3%.

Bear Case : EHC

The primary concerns for EHC are Debt/Equity.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Revenue Growth.

Key Dynamics to Monitor

EHC profiles as a value stock while NIVF is a declining play — different risk/reward profiles.

EHC carries more volatility with a beta of 0.61 — expect wider price swings.

EHC is growing revenue faster at 9.6% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EHC scores higher overall (71/100 vs 34/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Encompass Health Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a pioneering organization in the reproductive health industry, specializing in innovative fertility solutions, including advanced in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive technologies and is strategically positioned to capitalize on the growing global demand for fertility treatments, supported by a robust network of clinics and strategic partnerships. As the fertility services market continues to expand, NIVF is well-equipped for substantial growth, with a mission to assist individuals and couples in their journey to parenthood through forward-thinking healthcare solutions.

Want to dig deeper into these stocks?